BTLA and cancer: This review focuses on comprehensively examining current knowledge on the immunobiology of the inhibitory immune checkpoint BTLA (B- and T-lymphocyte attenuator) and its binding partner HVEM (Herpesvirus entry mediator), as well as currently available evidence supporting the clinical application of the BTLA/HVEM axis as a future target for cancer immunotherapy.